Smiths Detection and Novartis to Develop Infectious Disease Dxs Based on LATE PCR Tech
March 25, 2010
Smiths Detection and Novartis to Develop Infectious Disease Dxs Based on LATE PCR Tech
Smiths Detection Diagnostics and Novartis Diagnostics plan to develop and market highly multiplexed assays for a variety of infectious diseases, beginning with a focus on healthcare-associated infections.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- South African University Developing MDR/XDR-TB Assays Using Brandeis' LATE-PCR Tech
June 28, 2012 / PCR Insider - IP Watch: Roche, Sony, Akonni, Diasorin, Genomic Health, Smiths Detection Among US Patent Recipients
December 13, 2012 / PCR Insider - IP Watch: Roche, Smiths Detection, PSU, Advanced Liquid Logic, PositiveID Among US Patent Winners
March 20, 2012 / PCR Insider - Q&A: New Novartis Dx President Discusses Nucleic Acid Testing, Blood Screening Business
March 15, 2012 / PCR Insider - BD, Qiagen, MSKCC, Life Tech, Gen-Probe, Roche, MIT, Smiths Detection and Others Win US Patents
December 1, 2011 / PCR Insider